Shuo Wang

Shuo Wang

Auto-generated profile, based on publicly available information

Shuo Wang

Qingdao University, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2021 in Food & Function
Verified
Journal Article
Closed access
PDF file
Ningning HeNingning He
Ningning He
HCHao Chen
Hao Chen
ZZZihan Zhou
Zihan Zhou
WZWandong Zhao
Wandong Zhao
SWShuo Wang
Shuo Wang
SLShangyong Li
Shangyong Li
The composition and structure of gut microbiota plays an important role in obesity induced by a high-fat diet (HFD) and related metabolic syndrome (MetS).

23 September 2022
Verified
Conference Paper
Open access
SWShuo Wang
Shuo Wang
JZJunli Zhao
Junli Zhao
WLWeiwei Li
Weiwei Li
JTJieying Tang
Jieying Tang
XDXiaodan Deng
Xiaodan Deng
MZMingquan Zhou
Mingquan Zhou
The similarity evaluation of skull data is a research work of great significance and has been widely used in forensic, archaeology, and other fields. In this paper, we propose a 3D skull similarity evaluation method based on Siamese Network. Firstly, the original 3D skull data are mapped onto 2D depth images, which maintains the original information of the 3D data to the greatest extent. Then, we introduce the residual structure into the Siamese network to extract the main features of any pair of skull depth image data and map it to a new space for representation. Finally, a mapping function is proposed to calculate a reasonable similarity value of 0-1 between the two input skull data through the sigmoid layer. We conducted objective experiments on 3D skull models and compared them with the subjective skull similarity. The experimental results show that the 3D skull similarity evaluation method based on Siamese network with residual structure can effectively evaluate the similarity of skulls. The results are basically consistent with people's subjective evaluation, providing an effective direction for craniofacial reconstruction and identification.

27 May 2020 in Visceral Medicine
Verified
Journal Article
Open access
PDF file
HSHua-Sheng Shi
Hua-Sheng Shi
SWShuo Wang
Shuo Wang
MLMan-Jiang Li
Man-Jiang Li
LWLi-Qun Wu
Li-Qun Wu
Hepatocellular carcinoma (HCC) has a high degree of malignancy and poor prognosis. Treatment options for patients with advanced HCC are limited. There is currently no evidence to approve the accumulation of targeted therapies for HCC to support the inhibition of the PI3K/Akt/mTOR signaling pathway as an effective therapeutic strategy. We report on a patient with advanced HCC carrying the TSC1 gene mutation who responded well to the mammalian target of rapamycin inhibitor everolimus. Computed tomography revealed tumor shrinkage and maintenance of partial remission after everolimus treatment for >12.3 months. To the best of our knowledge, this is the first clinical case report showing benefit from everolimus treatment in HCC patients with TSC1 gene mutations. Therefore, everolimus may be used as a potential targeted therapy for HCC with TSC1 gene mutation.